These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

242 related articles for article (PubMed ID: 32264972)

  • 1. Sarilumab and adalimumab differential effects on bone remodelling and cardiovascular risk biomarkers, and predictions of treatment outcomes.
    Gabay C; Burmester GR; Strand V; Msihid J; Zilberstein M; Kimura T; van Hoogstraten H; Boklage SH; Sadeh J; Graham NMH; Boyapati A
    Arthritis Res Ther; 2020 Apr; 22(1):70. PubMed ID: 32264972
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Patient-reported outcomes from a randomized phase III trial of sarilumab monotherapy versus adalimumab monotherapy in patients with rheumatoid arthritis.
    Strand V; Gossec L; Proudfoot CWJ; Chen CI; Reaney M; Guillonneau S; Kimura T; van Adelsberg J; Lin Y; Mangan EK; van Hoogstraten H; Burmester GR
    Arthritis Res Ther; 2018 Jun; 20(1):129. PubMed ID: 29921318
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Association of High Serum Interleukin-6 Levels With Severe Progression of Rheumatoid Arthritis and Increased Treatment Response Differentiating Sarilumab From Adalimumab or Methotrexate in a Post Hoc Analysis.
    Boyapati A; Schwartzman S; Msihid J; Choy E; Genovese MC; Burmester GR; Lam G; Kimura T; Sadeh J; Weinreich DM; Yancopoulos GD; Graham NMH
    Arthritis Rheumatol; 2020 Sep; 72(9):1456-1466. PubMed ID: 32343882
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Sarilumab plus methotrexate suppresses circulating biomarkers of bone resorption and synovial damage in patients with rheumatoid arthritis and inadequate response to methotrexate: a biomarker study of MOBILITY.
    Boyapati A; Msihid J; Fiore S; van Adelsberg J; Graham NM; Hamilton JD
    Arthritis Res Ther; 2016 Oct; 18(1):225. PubMed ID: 27716324
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy and safety of sarilumab monotherapy versus adalimumab monotherapy for the treatment of patients with active rheumatoid arthritis (MONARCH): a randomised, double-blind, parallel-group phase III trial.
    Burmester GR; Lin Y; Patel R; van Adelsberg J; Mangan EK; Graham NM; van Hoogstraten H; Bauer D; Ignacio Vargas J; Lee EB
    Ann Rheum Dis; 2017 May; 76(5):840-847. PubMed ID: 27856432
    [TBL] [Abstract][Full Text] [Related]  

  • 6. High levels of interleukin-6 in patients with rheumatoid arthritis are associated with greater improvements in health-related quality of life for sarilumab compared with adalimumab.
    Strand V; Boklage SH; Kimura T; Joly F; Boyapati A; Msihid J
    Arthritis Res Ther; 2020 Oct; 22(1):250. PubMed ID: 33081825
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Safety and efficacy of switching from adalimumab to sarilumab in patients with rheumatoid arthritis in the ongoing MONARCH open-label extension.
    Burmester GR; Strand V; Rubbert-Roth A; Amital H; Raskina T; Gómez-Centeno A; Pena-Rossi C; Gervitz L; Thangavelu K; St John G; Boklage S; Genovese MC
    RMD Open; 2019; 5(2):e001017. PubMed ID: 31673415
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Efficacy and safety of sarilumab in combination with csDMARDs or as monotherapy in subpopulations of patients with moderately to severely active rheumatoid arthritis in three phase III randomized, controlled studies.
    Genovese MC; Fleischmann R; Kivitz A; Lee EB; van Hoogstraten H; Kimura T; St John G; Mangan EK; Burmester GR
    Arthritis Res Ther; 2020 Jun; 22(1):139. PubMed ID: 32522251
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effects of Sarilumab on Rheumatoid Arthritis as Reported by Patients Using the Rheumatoid Arthritis Impact of Disease Scale.
    Gossec L; Strand V; Proudfoot C; Chen CI; Guillonneau S; Kimura T; van Hoogstraten H; Mangan E; Reaney M
    J Rheumatol; 2019 Oct; 46(10):1259-1267. PubMed ID: 30877216
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Association between low hemoglobin, clinical measures, and patient-reported outcomes in patients with rheumatoid arthritis: results from post hoc analyses of three phase III trials of sarilumab.
    Rubbert-Roth A; Furst DE; Fiore S; Praestgaard A; Bykerk V; Bingham CO; Charles-Schoeman C; Burmester G
    Arthritis Res Ther; 2022 Aug; 24(1):207. PubMed ID: 36008838
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Interleukin-6 receptor blockade or TNFα inhibition for reducing glycaemia in patients with RA and diabetes: post hoc analyses of three randomised, controlled trials.
    Genovese MC; Burmester GR; Hagino O; Thangavelu K; Iglesias-Rodriguez M; John GS; González-Gay MA; Mandrup-Poulsen T; Fleischmann R
    Arthritis Res Ther; 2020 Sep; 22(1):206. PubMed ID: 32907617
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Sarilumab: Review of a Second IL-6 Receptor Antagonist Indicated for the Treatment of Rheumatoid Arthritis.
    Boyce EG; Rogan EL; Vyas D; Prasad N; Mai Y
    Ann Pharmacother; 2018 Aug; 52(8):780-791. PubMed ID: 29482351
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Sarilumab plus methotrexate in patients with active rheumatoid arthritis and inadequate response to methotrexate: results of a randomized, placebo-controlled phase III trial in Japan.
    Tanaka Y; Wada K; Takahashi Y; Hagino O; van Hoogstraten H; Graham NMH; Kameda H
    Arthritis Res Ther; 2019 Mar; 21(1):79. PubMed ID: 30894208
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Sarilumab plus methotrexate improves patient-reported outcomes in patients with active rheumatoid arthritis and inadequate responses to methotrexate: results of a phase III trial.
    Strand V; Kosinski M; Chen CI; Joseph G; Rendas-Baum R; Graham NM; van Hoogstraten H; Bayliss M; Fan C; Huizinga T; Genovese MC
    Arthritis Res Ther; 2016 Sep; 18(1):198. PubMed ID: 27600829
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparison of lipid and lipid-associated cardiovascular risk marker changes after treatment with tocilizumab or adalimumab in patients with rheumatoid arthritis.
    Gabay C; McInnes IB; Kavanaugh A; Tuckwell K; Klearman M; Pulley J; Sattar N
    Ann Rheum Dis; 2016 Oct; 75(10):1806-12. PubMed ID: 26613768
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Economic Evaluation of Sarilumab in the Treatment of Adult Patients with Moderately-to-Severely Active Rheumatoid Arthritis Who Have an Inadequate Response to Conventional Synthetic Disease-Modifying Antirheumatic Drugs.
    Muszbek N; Proudfoot C; Fournier M; Chen CI; Kuznik A; Kiss Z; Gal P; Michaud K
    Adv Ther; 2019 Jun; 36(6):1337-1357. PubMed ID: 31004324
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Rapid and sustained improvement in bone and cartilage turnover markers with the anti-interleukin-6 receptor inhibitor tocilizumab plus methotrexate in rheumatoid arthritis patients with an inadequate response to methotrexate: results from a substudy of the multicenter double-blind, placebo-controlled trial of tocilizumab in inadequate responders to methotrexate alone.
    Garnero P; Thompson E; Woodworth T; Smolen JS
    Arthritis Rheum; 2010 Jan; 62(1):33-43. PubMed ID: 20039425
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Sarilumab Plus Methotrexate in Patients With Active Rheumatoid Arthritis and Inadequate Response to Methotrexate: Results of a Phase III Study.
    Genovese MC; Fleischmann R; Kivitz AJ; Rell-Bakalarska M; Martincova R; Fiore S; Rohane P; van Hoogstraten H; Garg A; Fan C; van Adelsberg J; Weinstein SP; Graham NM; Stahl N; Yancopoulos GD; Huizinga TW; van der Heijde D
    Arthritis Rheumatol; 2015 Jun; 67(6):1424-37. PubMed ID: 25733246
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A review of sarilumab for the treatment of rheumatoid arthritis.
    Lee EB
    Immunotherapy; 2018 Jan; 10(1):57-65. PubMed ID: 29043871
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy and Safety of ABBV-3373, a Novel Anti-Tumor Necrosis Factor Glucocorticoid Receptor Modulator Antibody-Drug Conjugate, in Adults with Moderate-to-Severe Rheumatoid Arthritis Despite Methotrexate Therapy: A Randomized, Double-Blind, Active-Controlled Proof-of-Concept Phase IIa Trial.
    Buttgereit F; Aelion J; Rojkovich B; Zubrzycka-Sienkiewicz A; Chen S; Yang Y; Arikan D; D'Cunha R; Pang Y; Kupper H; Radstake T; Amital H
    Arthritis Rheumatol; 2023 Jun; 75(6):879-889. PubMed ID: 36512671
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.